Actively Recruiting
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Led by Isala · Updated on 2026-03-30
776
Participants Needed
1
Research Sites
274 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile. Infusion times will be gradually shortened if tolerability allowes.
CONDITIONS
Official Title
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab, ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab
- 18 years and older
- No known history of increased susceptibility to immunological reactions
- Able and willing to sign the Informed Consent Form before screening
You will not qualify if you...
- Use of other research medication within 4 weeks before starting the study
- Participation in medical research requiring strict medication timing and infusion dosages
- Dosage deviates from standard protocol
- Receiving drugs through a central venous catheter (e.g., port or porth-a-cath)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Isala Hospital
Zwolle, Netherlands, 8025AB
Actively Recruiting
Research Team
E
Elianne CS de Boer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here